Table III.

The top 40 most significant differentially methylated sites in the hepatocellular carcinoma group compared with the control group.

Gene	Regulation	P-value	Db-value
LYPD3	Up	1.13×10−11	0.26
FLJ21159	Up	1.70×10−11	0.26
ZNF154	Up	2.94×10−11	0.52
ZNF540	Up	7.96×10−11	0.33
GPR25	Up	8.68×10−11	0.20
MS4A3	Down	9.61×10−11	−0.23
LDHB	Up	1.62×10−10	0.44
ALOX12	Up	1.65×10−10	0.12
PRKG2	Down	1.99×10−10	−0.31
FLJ25773	Down	2.10×10−10	−0.24
PKDREJ	Up	2.14×10−10	0.17
TBC1D1	Up	2.47×10−10	0.13
SLC39A12	Down	2.94×10−10	−0.30
SERHL	Up	2.98×10−10	0.26
C6orf206	Up	3.19×10−10	0.32
C11orf2	Up	3.22×10−10	0.06
CCDC37	Up	3.39×10−10	0.32
LILRA1	Down	3.79×10−10	−0.21
OR51B4	Down	4.22×10−10	−0.27
HDAC1	Down	4.30×10−10	−0.05
XLF	Down	5.08×10−10	−0.04
KCTD4	Up	5.57×10−10	0.24
INA	Up	5.58×10−10	0.34
ABHD9	Up	6.00×10−10	0.42
AQP6	Down	6.06×10−10	−0.07
ANKRD33	Up	6.90×10−10	0.19
TSPYL5	Up	9.71×10−10	0.26
RPS6KC1	Down	1.19×10−9	−0.07
FLJ13149	Down	1.33×10−9	−0.06
FCAR	Down	1.38×10−9	−0.22
CD1B	Down	1.40×10−9	−0.23
KLK2	Down	1.50×10−9	−0.21
CDH18	Down	1.50×10−9	−0.34
BOLL	Up	1.67×10−9	0.24
SGNE1	Up	1.67×10−9	0.25
CYP11B1	Down	1.75×10−9	−0.38
S100A8	Down	1.92×10−9	−0.21
MAPKAP1	Down	2.01×10−9	−0.06
QTRT1	Down	2.21×10−9	−0.09
KLK9	Down	2.32×10−9	−0.20
FLJ46481	Down	2.35×10−9	−0.24